Vertex Pharmaceuticals Incorporated (VRTX)
Vertex Pharmaceuticals (VRTX) Rises But Trails Market: What Investors Should Know
In the most recent trading session, Vertex Pharmaceuticals (VRTX) closed at $512.52, indicating a +0.06% shift from the previous trading day.
Why the Market Dipped But Vertex Pharmaceuticals (VRTX) Gained Today
Vertex Pharmaceuticals (VRTX) concluded the recent trading session at $502.92, signifying a +1.51% move from its prior day's close.
Why Is Vertex (VRTX) Up 7.3% Since Last Earnings Report?
Vertex (VRTX) reported earnings 30 days ago. What's next for the stock?
Where Will Vertex Pharmaceuticals Be in 10 Years?
The past decade has been a game-changing one for Vertex Pharmaceuticals (VRTX 2.40%). The biotech won approval for its first cystic fibrosis (CF) drug -- Kalydeco -- back in 2012 and has since gained the regulatory nod for four more and become the global leader in the CF market.
Vertex Pharmaceuticals Incorporated (VRTX) Leerink's Global Healthcare Conference 2025 (Transcript)
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX ) Leerink's Global Healthcare Conference 2025 March 10, 2025 10:00 AM ET Company Participants Charlie Wagner - CFO and COO David Altshuler - Chief Scientific Officer Conference Call Participants Dave Risinger - Leerink Partners Dave Risinger Great. Well thanks very much, everyone, for joining us for our next session with Vertex.
If I Could Buy Only 1 Growth Stock, This Would Be It
There are hundreds of publicly traded companies on various equity markets worldwide. Investors choose to put their hard-earned money into specific companies based on their preferences, risk tolerance, goals, investment horizons, available capital, etc.
Vertex Pharmaceuticals Incorporated (VRTX) TD Cowen 45th Annual Health Care Conference (Transcript)
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX ) TD Cowen 45th Annual Health Care Conference Transcript March 3, 2025 3:10 PM ET Company Participants David Altshuler - Executive Vice President, Global Research and CSO Stuart Arbuckle - Executive Vice President and COO Conference Call Participants Phil Nadeau - TD Cowen Phil Nadeau Good afternoon. And welcome once again to TD Cowen's 45th Annual Healthcare Conference.
Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know
Vertex (VRTX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It
Vertex (VRTX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
The Ultimate Healthcare Stock to Buy With $500 Right Now
Healthcare isn't the hottest sector these days. While the S&P 500 has soared nearly 21% over the last 12 months, healthcare stocks as a group are barely in positive territory.
VRTX's Q4 Earnings Miss Mark, Revenues Beat on Higher Product Sales
Vertex reports mixed fourth-quarter 2024 results as earnings miss estimates while revenues beat the same. Trikafta/Kaftrio drive year-over-year sales.
Vertex Pharmaceuticals Incorporated (VRTX) Q4 2024 Earnings Call Transcript
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX ) Q4 2024 Earnings Conference Call February 10, 2025 4:30 PM ET Company Participants Susie Lisa - Senior Vice President, Investor Relations Reshma Kewalramani - President and Chief Executive Office Stuart Arbuckle - Chief Operating Officer Charlie Wagner - Chief Financial Officer Conference Call Participants Salveen Richter - Goldman Sachs Evan Seigerman - BMO Capital Markets Jessica Fye - JPMorgan Geoff Meacham - Citibank Michael Yee - Jefferies William Pickering - Bernstein Liisa Bayko - Evercore ISI Phil Nadeau - TD Cowen Eliana Merle - UBS Tazeen Ahmad - Bank of America Dave Risinger - Leerink Partners Olivia Brayer - Cantor Fitzgerald Operator Good day, and welcome to the Vertex Pharmaceuticals Fourth Quarter 2024 Earnings Call. All participants will be in a listen-only mode.
